Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
JCI Insight ; 3(12)2018 06 21.
Article in English | MEDLINE | ID: mdl-29925682

ABSTRACT

IgG antibodies are abundantly present in the vasculature but to a much lesser extent in mucosal tissues. This contrasts with antibodies of the IgA and IgM isotype that are present at high concentration in mucosal secretions due to active delivery by the polymeric Ig receptor (pIgR). IgG is the preferred isotype for therapeutic mAb development due to its long serum half-life and robust Fc-mediated effector function, and it is utilized to treat a diverse array of diseases with antigen targets located in the vasculature, serosa, and mucosa. As therapeutic IgG antibodies targeting the luminal side of mucosal tissue lack an active transport delivery mechanism, we sought to generate IgG antibodies that could be transported via pIgR, similarly to dimeric IgA and pentameric IgM. We show that an anti-Pseudomonas aeruginosa IgG fused with pIgR-binding peptides gained the ability to transcytose and be secreted via pIgR. Consistent with these results, pIgR-binding IgG antibodies exhibit enhanced localization to the bronchoalveolar space when compared with the parental IgG antibody. Furthermore, pIgR-binding mAbs maintained Fc-mediated functional activity and promoted enhanced survival compared with the parental mAb in a P. aeruginosa acute pneumonia model. Our results suggest that increasing IgG accumulation at mucosal surfaces by pIgR-mediated active transport can improve the efficacy of therapeutic mAbs that act at these sites.


Subject(s)
Immunoglobulin G/immunology , Immunoglobulin G/pharmacology , Mucous Membrane/immunology , Pseudomonas Infections/immunology , Pseudomonas aeruginosa/drug effects , Animals , Biological Transport/immunology , CHO Cells , Cricetulus , Dogs , Immunoglobulin A/immunology , Immunoglobulin M/immunology , Madin Darby Canine Kidney Cells , Mice, Inbred BALB C , Mucous Membrane/microbiology , Receptors, Polymeric Immunoglobulin , Secretory Component , Transcytosis/immunology
2.
MAbs ; 7(4): 743-51, 2015.
Article in English | MEDLINE | ID: mdl-25970007

ABSTRACT

Fc effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP) are crucial to the efficacy of many antibody therapeutics. In addition to IgG, antibodies of the IgA isotype can also promote cell killing through engagement of myeloid lineage cells via interactions between the IgA-Fc and FcαRI (CD89). Herein, we describe a unique, tandem IgG1/IgA2 antibody format in the context of a trastuzumab variable domain that exhibits enhanced ADCC and ADCP capabilities. The IgG1/IgA2 tandem Fc format retains IgG1 FcγR binding as well as FcRn-mediated serum persistence, yet is augmented with myeloid cell-mediated effector functions via FcαRI/IgA Fc interactions. In this work, we demonstrate anti-human epidermal growth factor receptor-2 antibodies with the unique tandem IgG1/IgA2 Fc can better recruit and engage cytotoxic polymorphonuclear (PMN) cells than either the parental IgG1 or IgA2. Pharmacokinetics of IgG1/IgA2 in BALB/c mice are similar to the parental IgG, and far surpass the poor serum persistence of IgA2. The IgG1/IgA2 format is expressed at similar levels and with similar thermal stability to IgG1, and can be purified via standard protein A chromatography. The tandem IgG1/IgA2 format could potentially augment IgG-based immunotherapeutics with enhanced PMN-mediated cytotoxicity while avoiding many of the problems associated with developing IgAs.


Subject(s)
Antibody-Dependent Cell Cytotoxicity/drug effects , Antigens, CD/immunology , Immunoglobulin G , Leukocytes/immunology , Phagocytosis/drug effects , Receptors, Fc/immunology , Animals , Antibody-Dependent Cell Cytotoxicity/immunology , Female , HEK293 Cells , Humans , Immunoglobulin A/immunology , Immunoglobulin A/pharmacology , Immunoglobulin G/immunology , Immunoglobulin G/pharmacology , Male , Mice , Mice, Inbred BALB C , Receptor, ErbB-2/antagonists & inhibitors , Receptor, ErbB-2/immunology , Receptors, IgG/immunology
3.
J Biol Chem ; 290(7): 4282-90, 2015 Feb 13.
Article in English | MEDLINE | ID: mdl-25538249

ABSTRACT

The Fc domain of IgG has been the target of multiple mutational studies aimed at altering the pH-dependent IgG/FcRn interaction to modulate IgG pharmacokinetics. These studies have yielded antibody variants with disparate pharmacokinetic characteristics, ranging from extended in vivo half-life to those exhibiting extremely rapid clearance. To better understand pH-dependent binding parameters that govern these outcomes and limit FcRn-mediated half-life extension, we generated a panel of novel Fc variants with high affinity binding at acidic pH that vary in pH 7.4 affinities and assessed pharmacokinetic outcomes. Pharmacokinetic studies in human FcRn transgenic mice and cynomolgus monkeys showed that multiple variants with increased FcRn affinities at acidic pH exhibited extended serum half-lives relative to the parental IgG. Importantly, the results reveal an underappreciated affinity threshold of neutral pH binding that determines IgG recycling efficiency. Variants with pH 7.4 FcRn affinities below this threshold recycle efficiently and can exhibit increased serum persistence. Increasing neutral pH FcRn affinity beyond this threshold reduced serum persistence by offsetting the benefits of increased pH 6.0 binding. Ultra-high affinity binding to FcRn at both acidic and neutral pH leads to rapid serum clearance.


Subject(s)
Antibodies, Monoclonal/pharmacokinetics , Histocompatibility Antigens Class I/physiology , Immunoglobulin G/physiology , Protein Engineering , Receptors, Fc/physiology , Animals , Antibodies, Monoclonal/genetics , Antibodies, Monoclonal/metabolism , Antibody Affinity , Bacteriophages , Female , Humans , Hydrogen-Ion Concentration , Macaca fascicularis , Male , Mice , Mice, Transgenic , Peptide Fragments/immunology , Peptide Fragments/metabolism , Peptide Library , Protein Binding , Protein Conformation , Surface Plasmon Resonance , Tissue Distribution
4.
Proc Natl Acad Sci U S A ; 102(24): 8466-71, 2005 Jun 14.
Article in English | MEDLINE | ID: mdl-15939870

ABSTRACT

Look-through mutagenesis (LTM) is a multidimensional mutagenesis method that simultaneously assesses and optimizes combinatorial mutations of selected amino acids. The process focuses on a precise distribution within one or more complementarity determining region (CDR) domains and explores the synergistic contribution of amino acid side-chain chemistry. LTM was applied to an anti-TNF-alpha antibody, D2E7, which is a challenging test case, because D2E7 was highly optimized (K(d) = 1 nM) by others. We selected and incorporated nine amino acids, representative of the major chemical functionalities, individually at every position in each CDR and across all six CDRs (57 aa). Synthetic oligonucleotides, each introducing one amino acid mutation throughout the six CDRs, were pooled to generate segregated libraries containing single mutations in one, two, and/or three CDRs for each V(H) and V(L) domain. Corresponding antibody libraries were displayed on the cell surface of yeast. After positive binding selection, 38 substitutions in 21 CDR positions were identified that resulted in higher affinity binding to TNF-alpha. These beneficial mutations in both V(H) and V(L) were represented in two combinatorial beneficial mutagenesis libraries and selected by FACS to produce a convergence of variants that exhibit between 500- and 870-fold higher affinities. Importantly, these enhanced affinities translate to a 15- to 30-fold improvement in in vitro TNF-alpha neutralization in an L929 bioassay. Thus, this LTM/combinatorial beneficial mutagenesis strategy generates a comprehensive energetic map of the antibody-binding site in a facile and rapid manner and should be broadly applicable to the affinity maturation of antibodies and other proteins.


Subject(s)
Amino Acids/chemistry , Antibodies/metabolism , Antibody Affinity/genetics , Binding Sites, Antibody/genetics , Gene Library , Mutagenesis, Site-Directed/genetics , Antibodies/genetics , Flow Cytometry , Mutation/genetics , Neutralization Tests , Tumor Necrosis Factor-alpha/metabolism , Yeasts
SELECTION OF CITATIONS
SEARCH DETAIL
...